drugset
Drugs / CM-CS1 T cells
last change Jun 2018 re-read 3 minutes ago

CM-CS1 T cells

also known as CM-CS1 cells

Cell therapy

Developed for
acute myeloid leukemia · myelodysplastic syndrome · plasma cell myeloma
Investigated by
Celyad Oncology SA · Dana-Farber Cancer Institute · National Heart, Lung, and Blood Institute (NHLBI)

Trials 1

today NCT02203825 · Ph 1
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT02203825 Mar 2015 → Mar 2018 acute myeloid leukemia, myelodysplastic syndrome, plasma cell myeloma Celyad Oncology SA Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as CM-CS1 T cells “chimeric-antigen receptor (CAR) T-cells (CM-CS1 T cells)” NCT02203825 ↗
1

“single dose of CM-CS1 T-cells by intravenous infusion” NCT02203825 ↗
Known as CM-CS1 cells “single infusion of CM-CS1 cells” NCT02203825 ↗
Modality Cell therapy “Adoptive cell therapy employing natural killer group 2D (NKG2D) chimeric antigen receptor (CAR)-modified T cells” PMID 30180944 ↗ Jun 2018
Route Intravenous “by intravenous infusion” NCT02203825 ↗